Lorenz M, Happ J, Hottenrott C, Maul F D, Baum R P, Hör G, Encke A
Nuklearmedizin. 1986 Feb;25(1):9-14.
A new tumor marker (CA 19-9) was investigated. CA 19-9 is a tumor-associated antigen which is detected by a monoclonal antibody. CA 19-9 (CIS-Centocor) was compared simultaneously with CEA (carcinoembryonic antigen) in 347 patients. 123 patients with gastrointestinal tumors showed a sensitivity of 31% for CA 19-9 (CEA 49%), combination increased sensitivity to 58%. The highest sensitivity was found in pancreas carcinoma (CA 19-9 75%, CEA 66%, combination 92%); it was lower in gastric, colon, and oesophagus carcinomas. In relapsed colorectal carcinomas sensitivity was 53% (CEA 78%, combination 85%). In cases of relapse, tumor markers may become positive even if they were not detectable before resection of the primary tumor. Specificity for CA 19-9 was 100% (CEA 84%) compared to a group of non-malignant diseases including patients with inflammations and patients with nicotin abuse (n = 102). Because of its high specificity and superior sensitivity to CEA in pancreas carcinomas CA 19-9 should be determined in primary and relapse diagnosis in combination with CEA.
对一种新的肿瘤标志物（CA 19-9）进行了研究。CA 19-9是一种肿瘤相关抗原，可通过单克隆抗体检测。在347例患者中，将CA 19-9（CIS-先灵葆雅公司生产）与癌胚抗原（CEA）同时进行比较。123例胃肠道肿瘤患者中，CA 19-9的敏感性为31%（CEA为49%），联合检测可将敏感性提高至58%。胰腺癌的敏感性最高（CA 19-9为75%，CEA为66%，联合检测为92%）；胃癌、结肠癌和食管癌的敏感性较低。复发性结直肠癌的敏感性为53%（CEA为78%，联合检测为85%）。在复发病例中，即使在原发性肿瘤切除前无法检测到肿瘤标志物，它们也可能呈阳性。与包括炎症患者和尼古丁滥用患者在内的一组非恶性疾病患者（n = 102）相比，CA 19-9的特异性为100%（CEA为84%）。由于CA 19-9具有高特异性，且在胰腺癌中对CEA具有更高的敏感性，因此在原发性和复发诊断中应将其与CEA联合检测。
